BRPI0409424A - composição farmacêutica para admistração parenteral, método de tratamento de um paciente sofrendo de hemofilia, uso de uma partìcula coloidal, e, método de tratamento de um paciente sofrendo de uma doença - Google Patents
composição farmacêutica para admistração parenteral, método de tratamento de um paciente sofrendo de hemofilia, uso de uma partìcula coloidal, e, método de tratamento de um paciente sofrendo de uma doençaInfo
- Publication number
- BRPI0409424A BRPI0409424A BRPI0409424-7A BRPI0409424A BRPI0409424A BR PI0409424 A BRPI0409424 A BR PI0409424A BR PI0409424 A BRPI0409424 A BR PI0409424A BR PI0409424 A BRPI0409424 A BR PI0409424A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- patient suffering
- pharmaceutical composition
- parenteral administration
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA PARA ADMIMSTRAçãO PARENTERAL, MéTODO DE TRATAMENTO DE UM PACIENTE SOFRENDO DE HEMOFILIA, USO DE UMA PARTìCULA COLOIDAL, E, MéTODO DE TRATAMENTO DE UM PACIENTE SOFRENDO DE UMA DOENçA". Uma composição farmacêutica para administração parenteral compreendendo uma quantidade terapeuticamente efetiva de uma proteína ou um polipeptídeo e partículas coloidais. As partículas compreendem aproximadamente 1-20 porcento em mol de um lipídeo anfipático derivado com um polímero hidrofílico biocompatível. A proteína ou o polipeptídeo é selecionada(o) do grupo consistindo de: (a) proteínas ou polipeptídeos capazes de se ligar externamente nas citadas partículas coloidais; (b) proteínas ou polipeptídeos capazes de se ligar em polímeros de famílias de poli(alquiléter), poli(ácido lático) e poli(ácido glicólico); e (c) proteínas ou polipeptídeos que incluem uma seqüência de consenso de S/T-X/I/V-I/V/Q/SS/T-X-X-X-E, na qual X pode ser qualquer aminoácido, e S, T, L, I, E, e Q possuem os significados padrão. A proteína ou o polipeptídeo não é Fator VIII (FVIII) e não está encapsulada(o) nas partículas coloidais.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46270103P | 2003-04-15 | 2003-04-15 | |
US60/462,701 | 2003-04-15 | ||
PCT/IL2004/000327 WO2004091723A1 (en) | 2003-04-15 | 2004-04-15 | Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0409424A true BRPI0409424A (pt) | 2006-04-25 |
BRPI0409424B1 BRPI0409424B1 (pt) | 2018-05-02 |
BRPI0409424B8 BRPI0409424B8 (pt) | 2021-05-25 |
Family
ID=33299976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0409424A BRPI0409424B8 (pt) | 2003-04-15 | 2004-04-15 | composição farmacêutica para administração parenteral, e, usos de uma partícula coloidal e de partículas coloidais e uma proteína ou um polipeptídeo |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070167359A1 (pt) |
EP (1) | EP1633440B1 (pt) |
JP (1) | JP2006523683A (pt) |
CN (1) | CN1774281B (pt) |
AT (1) | ATE395101T1 (pt) |
AU (1) | AU2004229253B2 (pt) |
BR (1) | BRPI0409424B8 (pt) |
CA (1) | CA2522179C (pt) |
DE (1) | DE602004013769D1 (pt) |
DK (1) | DK1633440T3 (pt) |
ES (1) | ES2307009T3 (pt) |
MX (1) | MXPA05010926A (pt) |
PL (1) | PL1633440T3 (pt) |
PT (1) | PT1633440E (pt) |
WO (1) | WO2004091723A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2554161A1 (en) * | 2011-08-02 | 2013-02-06 | LFB Biotechnologies | Pharmaceutical composition comprising factor VII encapsulated in micelles |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
GB201518170D0 (en) * | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
GB201518171D0 (en) * | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
GB201518172D0 (en) * | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4348384A (en) * | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
CA2006596C (en) * | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
JPH0482839A (ja) * | 1990-07-20 | 1992-03-16 | Green Cross Corp:The | 蛋白質類・脂質小体複合体 |
NZ260909A (en) * | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
AU1916295A (en) * | 1994-02-08 | 1995-08-29 | Amgen, Inc. | Oral delivery of chemically modified proteins |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
JP2001508783A (ja) * | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | Peg化法 |
WO1999055306A1 (en) * | 1998-04-27 | 1999-11-04 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
DE60026030T2 (de) * | 1999-07-14 | 2006-08-10 | Alza Corp., Mountain View | Neutrales lipopolymer und liposomale zusammensetzungen daraus |
CA2400374A1 (en) * | 2000-02-18 | 2001-08-23 | Adrian Gilbert | Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
WO2002086117A1 (en) * | 2001-04-20 | 2002-10-31 | The University Of Vermont | Compositions and methods to control bleeding |
JP2005521645A (ja) * | 2001-12-04 | 2005-07-21 | ベン グリオン ユニバーシティ オブ ザ ネジェブ リサーチ アンド ディベラップメント オーソリティ | 器官特異的薬物ターゲティング用両親媒性化合物及び小胞/リポソーム |
-
2004
- 2004-04-15 DK DK04727664T patent/DK1633440T3/da active
- 2004-04-15 PT PT04727664T patent/PT1633440E/pt unknown
- 2004-04-15 MX MXPA05010926A patent/MXPA05010926A/es active IP Right Grant
- 2004-04-15 JP JP2006507607A patent/JP2006523683A/ja active Pending
- 2004-04-15 AU AU2004229253A patent/AU2004229253B2/en not_active Expired
- 2004-04-15 CA CA2522179A patent/CA2522179C/en not_active Expired - Fee Related
- 2004-04-15 ES ES04727664T patent/ES2307009T3/es not_active Expired - Lifetime
- 2004-04-15 AT AT04727664T patent/ATE395101T1/de not_active IP Right Cessation
- 2004-04-15 PL PL04727664T patent/PL1633440T3/pl unknown
- 2004-04-15 BR BRPI0409424A patent/BRPI0409424B8/pt active IP Right Grant
- 2004-04-15 US US10/553,357 patent/US20070167359A1/en not_active Abandoned
- 2004-04-15 DE DE602004013769T patent/DE602004013769D1/de not_active Expired - Lifetime
- 2004-04-15 EP EP04727664A patent/EP1633440B1/en not_active Expired - Lifetime
- 2004-04-15 CN CN2004800100998A patent/CN1774281B/zh not_active Expired - Lifetime
- 2004-04-15 WO PCT/IL2004/000327 patent/WO2004091723A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US20070167359A1 (en) | 2007-07-19 |
MXPA05010926A (es) | 2005-11-25 |
BRPI0409424B1 (pt) | 2018-05-02 |
CN1774281A (zh) | 2006-05-17 |
PT1633440E (pt) | 2008-08-25 |
ATE395101T1 (de) | 2008-05-15 |
EP1633440A1 (en) | 2006-03-15 |
CA2522179C (en) | 2012-02-14 |
AU2004229253B2 (en) | 2009-11-05 |
PL1633440T3 (pl) | 2008-12-31 |
DK1633440T3 (da) | 2008-09-08 |
JP2006523683A (ja) | 2006-10-19 |
WO2004091723A1 (en) | 2004-10-28 |
DE602004013769D1 (de) | 2008-06-26 |
BRPI0409424B8 (pt) | 2021-05-25 |
AU2004229253A1 (en) | 2004-10-28 |
CN1774281B (zh) | 2010-10-13 |
ES2307009T3 (es) | 2008-11-16 |
EP1633440B1 (en) | 2008-05-14 |
CA2522179A1 (en) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105189532B (zh) | 用于伤口愈合、皮肤护理和化妆品应用的自组装超短肽水凝胶 | |
EP1120439B1 (en) | Injectable ceramic compositions and methods for their preparation and use | |
BR0007597A (pt) | Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral | |
JP2006131648A (ja) | コラーゲンベースの注入可能な薬剤送達製剤およびその使用 | |
JPH11512740A (ja) | 増殖因子を含むゲル組成物 | |
US8029769B2 (en) | Protein formulation | |
Takaoka et al. | Bone regeneration by lactoferrin released from a gelatin hydrogel | |
MXPA05002991A (es) | Analogos de ghrh. | |
JP2001521414A (ja) | 移植可能なパテ状材料 | |
BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
DE69819488D1 (de) | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes | |
MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
JP2022552832A (ja) | タンパク質の送達のための組成物 | |
Silva et al. | Inflammatory response to dextrin-based hydrogel associated with human mesenchymal stem cells, urinary bladder matrix and Bonelike® granules in rat subcutaneous implants | |
US20050244393A1 (en) | Sealant or tissue generating product | |
BRPI0409424A (pt) | composição farmacêutica para admistração parenteral, método de tratamento de um paciente sofrendo de hemofilia, uso de uma partìcula coloidal, e, método de tratamento de um paciente sofrendo de uma doença | |
CA2589095C (en) | Protein formulation for administering an active enamel substance | |
BR9202374A (pt) | Composicao implantavel para a administracao parenteral de uma quantidade essencialmente uniforme e continua de uma proteina,um peptideo ou polipeptideo biologicamente ativos,processo de elevar e manter elevados niveis no sangue de uma proteina,peptideo ou polipeptideo biologicamente ativos e processo para a preparacao da composicao implantavel | |
JPH06157339A (ja) | 骨形成組成物及びその使用方法 | |
US20050112087A1 (en) | Pharmaceutical formulations for sustained drug delivery | |
EP1862170A1 (en) | Protein formulation | |
US20230010110A1 (en) | Histatin-1 formulation for the treatment, repair or regeneration of bone tissue in a subject | |
AU2011203284B2 (en) | Protein Formulation | |
WO2004032863A3 (en) | Oral formulations for proteins and polypeptides | |
JPH10167987A (ja) | 徐放性製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED (MT) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |